Thursday, January 19
Time: 12:15 PM – 1:00 PM
Location: Posters, Exhibits, and Food Room
Title: Applications of personalized ctDNA testing to optimize treatment decisions in patients with GI cancers
Description: Please join our Industry Expert Theater as we take a closer look at the clinical utility of personalized ctDNA testing for molecular residual disease assessment to address some of the common challenges physicians face when managing their patients with GI cancer.
Company: Natera, Inc.
Presenter: Adham Jurdi, MD- Medical Director, Oncology
Time: 5:00 PM – 5:45 PM
Location: Posters, Exhibits, and Food Room
Title: Redefining Cancer Care: The Importance of Genomic Driven Oncology
Description: A genomic-driven approach to oncology is rapidly evolving. We will discuss the emerging science on genomic alterations, which includes both genetic mutations and pathogenic gene fusions; including NRG1. We will also discuss the benefits of comprehensive RNA-based NGS testing.
Company: Merus
Presenter: Dan Hennessy Vice President, Medical Affairs
Friday, January 20
Time: 12:15 PM – 1:00 PM
Location: Posters, Exhibits, and Food Room
Title: Expanding Treatment Approaches for Unresectable Hepatocellular Carcinoma and Locally Advanced or Metastatic Biliary Tract Cancer
Description: An overview of hepatobiliary cancers followed by summaries of data from the HIMALAYA study of IMFINZI + IMJUDO in unresectable hepatocellular carcinoma and the TOPAZ-1 study of IMFINZI + gemcitabine/cisplatin in locally advanced and metastatic biliary tract cancer.
Company: AstraZeneca
Presenter: Stephen Valerio, US Medical Lead – IO
Time: 4:45 PM – 5:30 PM
Location: Posters, Exhibits, and Food Room
Title: PEMAZYRE (pemigatinib): The First FDA-Approved Treatment for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with an FGFR2 Fusion or Rearrangement
Description: Hear Dr. Susan Snodgrass of Incyte present key data from the FIGHT-202 study, a trial evaluating the use of PEMAZYRE in cholangiocarcinoma patients with FGFR2 fusions or rearrangements
Company: Incyte Corporation
Presenter: Susan Snodgrass, MD – Vice President, US Medical Affairs
For more information: https://conferences.asco.org/gi/industry-expert-theater
Leave a Reply